Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 18/20 | 0.59 |
| ▸ | ROCK1 | Q13464 | 4/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.49 |
| ▸ | CDC42BPA | Q5VT25 | 2/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | AURKA | O14965 | 2/20 | 0.47 |
| ▸ | GRK2 | P25098 | 2/20 | 0.47 |
| ▸ | RPS6KA1 | Q15418 | 2/20 | 0.47 |
| ▸ | PRKCB | P05771 | 1/20 | 0.47 |
| ▸ | AKT1 | P31749 | 1/20 | 0.47 |
| ▸ | GRK5 | P34947 | 1/20 | 0.47 |
| ▸ | GRK6 | P43250 | 1/20 | 0.47 |
| ▸ | CAMK2B | Q13554 | 1/20 | 0.47 |
| ▸ | GRK7 | Q8WTQ7 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20985827 | 0.88 | ROCK2 (0.60) | ROCK2 | |
| SCHEMBL28266159 | 0.84 | LMNA (0.44) | ROCK2 | |
| SCHEMBL20985847 | 0.81 | ROCK2 (0.64) | ROCK2ROCK1AURKAGRK2RPS6KA1 | |
| SCHEMBL20985759 | 0.80 | ROCK2 (0.55) | ROCK2ROCK1 | |
| SCHEMBL20985824 | 0.78 | ROCK2 (0.60) | ROCK2ROCK1GRK2 | |
| SCHEMBL20985756 | 0.77 | ROCK2 (0.57) | ROCK2ROCK1AURKAGRK2RPS6KA1 | |
| SCHEMBL20985772 | 0.76 | ROCK2 (0.56) | ROCK2 | |
| SCHEMBL20985798 | 0.76 | ROCK2 (0.56) | ROCK2 | |
| SCHEMBL16915088 | 0.74 | PKM (0.67) | ROCK2ROCK1AURKAGRK2RPS6KA1 | |
| SCHEMBL19643173 | 0.74 | ROCK2 (1.00) | ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10562887-B2 | Triazolones and tetrazolones as inhibitors of ROCK | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-02-18 | — | — | US | disclosed |
| US-20190152956-A1 | TRIAZOLONES AND TETRAZOLONES AS INHIBITORS OF ROCK | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-05-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190152956-A1 | TRIAZOLONES AND TETRAZOLONES AS INHIBITORS OF ROCK | MYLK, ROCK1, MYLK2 | ROCK2 5/4885ROCK1 2/4885CYP2C9 2193/4885 |
| US-10562887-B2 | Triazolones and tetrazolones as inhibitors of ROCK | MYLK, ROCK1, MYLK2 | ROCK2 5/4885ROCK1 2/4885CYP2C9 2193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.